Biotech Values

[Mpower]

Thanks for the clarification. It is also interesting that Sanofi was explicit in asserting their expectation for further erosion in the coming quarters as a result of the new generic competition. This is to some extent shocking, since MNTA/Sandoz control ~half the Lovenox market in the 3Q. How much more are they expecting to lose? Further erosion of SNY's Lovenox is a major positive for MNTA.